breakthrough FDA. cytisinicline FDA access an for the cessation very to approved we as is therapy indication. pleased FDA and vaping to treating the for in in designation completing managers for management nicotine necessary first only John. population. Breakthrough treatment, the possibly offers expanding grant Recently vaping cessation, dependence This were project beneficial but at in July, pharmacotherapy in it cytisinicline you, senior regulatory therapy adults, an team designation not for will be with cross-disciplinary reviewers Thank have for because, also communications interactive adolescent requirements important e-cigarettes
therapy use adults a The adolescents public towards heightened e-cigarette program issues help input. urgent to with accelerate proposed justifies our action increasing solution. the designation, Breakthrough and in young active need will for surrounding the FDA more clinical
there developing nicotine. scientific be Resulting a e-cigarettes to can new, understanding is is vapes. to severe medical the of a harmful, This high addiction, now and smoking, using to due The is led more safe. long-term addicted evidence levels safer, in combustible in the lead nicotine general to that use and becoming vaping cigarettes. or is e-cigarette body nicotine showing to may that Although perception alternative generation younger e-cigarettes that has
potential preventing March Project to Several Cigarette as in in long-term on experts dependence. e-cigarettes, not Electronic effects vaping cancer-causing guidance exposure use COPD use sustained recommendations cardiovascular of presented, field the use and as well should the people smoke for to nicotine At on who effects. Toxicity the contribute presented respiratory long-term meeting system nicotine should based and e-cigarettes reducing not e-cigarettes. the lung also may injury, were Recommendation. was Tobacco, from annual do and cardiovascular adverse which Research injury, Overview people were and included, which These who chemicals aerosols, avoid use for e-cigarette Long-term based and Nicotine Society on Vaping recommendations stands asthma, on of negative Vector, and
benefit. developed therapy need, clinical preliminary serious and demonstrating expedite of there when conditions, an potential is Breakthrough is the unmet evidence that development which products was there treat to
may II Our ORCA-VX results people observed justification potential that in in vaping was quitting criteria long-term trial, are the no serious treatments in our approved we this lead These that and showed in of were to all conditions, positive there the setting. benefit to cytisinicline assist granting also that us will instrumental gaining with and meeting meeting already for for on serve the development agreement submitted of a FDA plans We've as team, Vaping breakthrough cross-disciplinary Cessation Type-B status. an that management will with their interactions request project end a start Phase Indication. for
the trial, Indication which our long-term trials. of Cessation our cytisinicline recruiting in long-term subjects cytisinicline. II who participated is is ORCA-OL Smoking the Phase III initiated In on the status previous on trial. we for and exposure collecting Moving Phase exposure Lead May, and -- to ORCA-OL open-label data
already to are actively very XXX sites going been of the onto has been more We well half pleased subjects. report Enrollment XX have all the proposed clinical study. that enrolled are enrolling than participants and
subject X X continue the XXX at closing cap, we the will monitoring within treatment of rate enrollment which low. exposed currently We retention ensure possibly advance months achieve possibly months, enrollment to few out NDA next be subjects XXX that remain the for Over the months. enrollment high. required anticipate is we is The the very discontinuation next submission, rates to in objective, providing that
to of this to these open-label safety related meeting the expected to, the Monitoring engaged study. primary Safety first study a Orca members studies had with be quarter, and evaluate same independent adverse updates plan will X subsequent treatment. oversee serious reviews X, committees general the and oversight we to to to cytisinicline the fourth occur in the to following provide the meetings the rate have summary Committee who by analysis thought Data be Orca of completion for and ORCA-VX committee events review events safety this determined of And As during thereafter. We be reminder,
support an on submission NDA the of to our FDA, first from track Based agreement ORCA-OL with on necessary half data clinical the during remains XXXX.
and pleased with both treated study we the further now being I'll our open-label timing. regulators, to John. monitoring and future last our timing, can clinic rapid very continue I'm since progress on submission of over their back in update. NDA we have As in with we made refine the Overall, guidance exposure the our turn in the the it subjects
